secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001193125-22-216168
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inovio reports Q2 net loss $108.5M, extends cash runway into Q3 2024 via restructuring; appoints new CMO
--------------------------------------------------------------------------------

- Net loss $108.5M ($0.46 per share) vs $82.1M loss a year ago; revenue $784K (up from $273K).
- Operating expenses $104.9M, up from $83.5M; includes $14M non-cash litigation settlement and $6.9M severance.
- Cash & investments $348.1M at June 30; expects cash burn ~$73M in Q3, runway into Q3 2024.
- Restructuring: 18% workforce reduction, 86% contractor cut; expects 30% OpEx reduction; $1.6M charge in Q3.
- Appointed Dr. Michael Sumner as CMO; positive Phase 1/2 data for INO-5401 in GBM at ASCO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000119312522216168/0001193125-22-216168-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000119312522216168/d373738d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-216168

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer